Aurobindo Pharma, MSN Labs seek DGCI nod for Phase-III trials of Merck's molnupiravir

In a meeting held on October 4, both the companies said that they “they want to discontinue phase III trial in moderate Covid-19 patients and continue the phase III trial in mild Covid patients", as per the minutes of the meeting. ET has seen the minutes of the SEC meeting.

via Economictimes

No comments